Potassium Carbonate → 3-[2'-(2,3-dihydroindole-1-carbonyl)-3,4,5,6-tetrahydro-2H-1,4'-bipyridinyl-4-yl]-1,3,4,5-tetrahydro-1,3-benzodiazepin-2-one
反応式
Cl[C:2]1[CH:7]=[CH:6][N:5]=[C:4]([C:8]([N:10]2[C:18]3[C:13](=[CH:14][CH:15]=[CH:16][CH:17]=3)[CH2:12][CH2:11]2)=[O:9])[CH:3]=1.C(=O)([O-])[O-].[K+].[K+].[NH:25]1[CH2:30][CH2:29][CH:28]([N:31]2[CH2:37][CH2:36][C:35]3[CH:38]=[CH:39][CH:40]=[CH:41][C:34]=3[NH:33][C:32]2=[O:42])[CH2:27][CH2:26]1>C1COCC1>[N:10]1([C:8]([C:4]2[CH:3]=[C:2]([N:25]3[CH2:26][CH2:27][CH:28]([N:31]4[CH2:37][CH2:36][C:35]5[CH:38]=[CH:39][CH:40]=[CH:41][C:34]=5[NH:33][C:32]4=[O:42])[CH2:29][CH2:30]3)[CH:7]=[CH:6][N:5]=2)=[O:9])[C:18]2[C:13](=[CH:14][CH:15]=[CH:16][CH:17]=2)[CH2:12][CH2:11]1参加物
5
反応物 3
生成物 1
試薬・触媒・溶媒 1
実験手順
110 mg (0.43 mmol) (4-chloro-pyridin-2-yl)-(2,3-dihydro-indol-1-yl)-methanone, 150 mg (1.0 mmol) potassium carbonate and 100 mg (0.41 mmol) 3-piperidin-4-yl-1,3,4,5-tetrahydro-1,3-benzodiazepin-2-one in 10 mL THF were refluxed for 3 days. Then the reaction mixture was evaporated down using the rotary evaporator, taken up in 20 mL xylene and refluxed for a further 3 days. The solid was filtered off and the filtrate evaporated down i. vac. The residue was dissolved in DMF and purified by preparative HPLC. The product fractions were combined and lyophilised.
後処理
- customThen the reaction mixture was evaporated down
- customthe rotary evaporator
- temperaturerefluxed for a further 3 days
- filtrationThe solid was filtered off
- customthe filtrate evaporated down i
- dissolutionThe residue was dissolved in DMF
- custompurified by preparative HPLC
出典と根拠
- ORDレコード
- ord-a713b8b762d3463ca804602f6597b9ec
- 出典データセット
- uspto-grants-2014_09
- 特許番号
- US08829006B2
反応ノート
読み込み中…